Genetic research advance yields new lupus treatment

The Wall Street Journal, March 10, 2011
The Food and Drug Administration approved the first new drug for lupus in more than 50 years, a major milestone in the effort to mine data from the human genome to discover and develop new medicines. The drug, called Benlysta, will be co-marketed by Human Genome Sciences Inc., a Rockville, MD, company that has been on a roller-coaster journey for nearly two decades to develop the medicine, and GlaxoSmithKline PLC, whose investment in the biotech company was one of the first big bets a major pharmaceutical company placed on genomic research. Analysts expect the drug to reach blockbuster status, with sales eventually topping $1 billion a year.

Comments are moderated. Please be patient.


MOST POPULAR

SPONSORED REPORTS
SPONSORED HEADLINES

SIGN UP

FREE e-Newsletters Join the Council Subscribe to HL magazine

SPONSORSHIP & ADVERTISING

100 Winners Circle Suite 300
Brentwood, TN 37027

800-727-5257

About | Advertise | Terms of Use | Privacy Policy | Reprints/Permissions | Contact
© HealthLeaders Media 2014 a division of BLR All rights reserved.